Treatment De-Intensification for Patients With HPV-Positive Head and Neck Cancers

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Cisplatin and 70 Gy of intensity-modulated radiotherapy remain the standard of care (SoC) in HPV-positive head and neck cancer, with no data to support de-escalation as a new SoC. Cetuximab compromises locoregional tumor control and overall survival without reduced toxicity, although with different toxicity. Eliminating cisplatin and reducing radiation by 10 Gy compromise progression-free survival but not overall survival, and replacement of SoC adjuvant chemoradiotherapy with low-dose radiotherapy plus docetaxel compromises progression-free survival for patients with extracapsular extension and/or multiple cervical metastases, without significantly reducing grade 3 toxicities. The current trend toward numerous, single-institution phase II trials should be minimized, because they can be difficult to interpret. Instead, to move the field forward with more definitive outcomes, focus should be placed on taking promising concepts to multicenter, randomized phase II/III studies with clear statistical endpoints.

Original languageEnglish (US)
Pages (from-to)596-599
Number of pages4
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume20
Issue number5.5
DOIs
StatePublished - Jun 2022

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Treatment De-Intensification for Patients With HPV-Positive Head and Neck Cancers'. Together they form a unique fingerprint.

Cite this